Cedo Bagi received the M.D. and M.S. degrees in Zagreb, Croatia. He is a Senior Research Fellow at the Worldwide Science & Technology Division of Pfizer. Inc., having more than 20 years of research experience in academia and pharmaceutical industry. He is working in the areas of metabolic bone disease, oncology, and inflammation. His current research interests are focused on validation and implementation of translational preclinical models and technologies aimed to provide preclinical and clinical tools that will enable translation of novel medicines to clinic and ultimately help patients. Examples of areas of his expertise include validation/implementation of humanized liver models to assess PK/PD, safety and efficacy of novel compounds, and the use of orthotopic models to test combination therapies in oncology and validate and implement noninvasive technologies such as DigiGait and dynamic weight-bearing system to assess pain in various pain-models (arthritis, cancer, and fracture). Dr. Bagi applies his expertise in metabolic bone diseases, rheumatology, and bone oncology to help evaluate effect of new drugs on musculoskeletal system. Scientists in his team are pursuing use of noninvasive imaging technologies such as Micro-CT, pQCT, DEXA, high-frequency ultra sound, MRI, DigiGait, dynamic weight-bearing (Bioseb) system, and IVIS to advance novel compounds to clinic. Dr. Bagi is member of Pfizer TSN 100 and a Member of several professional organizations including International Bone and Mineral Society and Cancer Induced Bone Disease Society. His current interests are related to development, validation, and implementation of animal models that can be used to assess disease therapies such as anticancer, anti-inflammatory, and antifracture in conjunction with antipain therapies.
Biography Updated on 4 November 2010